OSR Holdings Amends S-1 for Continuous Offering
Ticker: OSRHW · Form: S-1/A · Filed: Jun 10, 2025 · CIK: 1840425
| Field | Detail |
|---|---|
| Company | Osr Holdings, Inc. (OSRHW) |
| Form Type | S-1/A |
| Filed Date | Jun 10, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: S-1/A, Medical Devices, Emerging Growth Company, Continuous Offering, SEC Filing, Surgical Instruments, Capital Raise
Related Tickers: OSRHW
TL;DR
**OSR Holdings is pushing forward with its public offering, signaling a potential capital injection for its medical device ambitions, but it's still an emerging growth play.**
AI Summary
OSR Holdings, Inc. filed an S-1/A on June 10, 2025, as an amendment to its initial S-1 registration statement, indicating a proposed sale of securities on a delayed or continuous basis under Rule 415. The company, formerly Bellevue Life Sciences Acquisition Corp. until January 13, 2021, operates in the surgical and medical instruments and apparatus sector. While specific revenue and net income figures are not detailed in this amendment, the filing confirms its status as an emerging growth company and a non-accelerated filer. The primary business change highlighted is the ongoing registration process for public offering, with the company's principal executive offices located at 10900 NE 4th Street, Suite 2300, Bellevue, WA 98004. Key risks include those inherent in a continuous offering and the general market risks for an emerging growth company in the medical device industry. The strategic outlook involves leveraging the capital raised from this offering to further its operations in surgical and medical instruments.
Why It Matters
This S-1/A filing signals OSR Holdings' intent to proceed with a continuous public offering, providing potential liquidity for investors and capital for the company's growth in the competitive surgical and medical instruments market. For employees, it could mean increased stability and expansion opportunities as the company secures funding. Customers might benefit from enhanced product development and market reach. In the broader market, this offering adds another player to the medical device sector, intensifying competition with established companies like Medtronic and Johnson & Johnson.
Risk Assessment
Risk Level: medium — OSR Holdings is classified as an 'emerging growth company' and a 'non-accelerated filer,' which typically implies less stringent reporting requirements and potentially higher investment risk compared to larger, more established companies. The filing indicates a 'delayed or continuous basis' offering under Rule 415, which can introduce market volatility and uncertainty regarding the timing and pricing of future sales.
Analyst Insight
Investors should closely monitor the effectiveness of this S-1/A and the subsequent pricing of OSR Holdings' securities, as the continuous offering could present entry points. Given its 'emerging growth company' status, a deeper dive into its financial performance and product pipeline is crucial before making any investment decisions.
Executive Compensation
| Name | Title | Total Compensation |
|---|---|---|
| Kuk Hyoun Hwang | Chief Executive Officer | |
| Jun Chul Whang | Chief Legal Officer |
Key Numbers
- 2025-06-10 — Filing Date (Date S-1/A was filed with the SEC)
- 0001840425 — Central Index Key (CIK) (Unique identifier for OSR Holdings, Inc.)
- 3841 — SIC Code (Standard Industrial Classification for Surgical & Medical Instruments & Apparatus)
- 84-5052822 — IRS Employer Identification Number (EIN) (Tax identification number for OSR Holdings, Inc.)
- 2021-01-13 — Date of Name Change (When the company changed from Bellevue Life Sciences Acquisition Corp. to OSR Holdings, Inc.)
- 425-635-7700 — Business Phone Number (Primary contact number for OSR Holdings, Inc.)
Key Players & Entities
- OSR Holdings, Inc. (company) — Registrant and medical device company
- Bellevue Life Sciences Acquisition Corp. (company) — Former name of OSR Holdings, Inc. until 2021-01-13
- Kuk Hyoun Hwang (person) — Chief Executive Officer of OSR Holdings, Inc.
- Jun Chul Whang (person) — Chief Legal Officer of OSR Holdings, Inc.
- Jacqueline Jamin Drohan, Esq. (person) — Legal counsel from Drohan Lee LLP
- Drohan Lee LLP (company) — Law firm providing counsel for OSR Holdings, Inc.
- SEC (regulator) — Securities and Exchange Commission
- Rule 415 (regulator) — SEC rule for delayed or continuous offerings
- 333-287626 (regulator) — Registration No. for the S-1 filing
- 1933 Act (regulator) — Securities Act of 1933
FAQ
What is the purpose of OSR Holdings' S-1/A filing?
The S-1/A filing by OSR Holdings, Inc. on June 10, 2025, is an amendment to its initial S-1 registration statement, indicating a proposed sale of securities on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933.
Who is the CEO of OSR Holdings, Inc.?
Kuk Hyoun Hwang is the Chief Executive Officer of OSR Holdings, Inc., with business operations located at 10900 NE 4th Street, Suite 2300, Bellevue, WA 98004.
What industry does OSR Holdings, Inc. operate in?
OSR Holdings, Inc. operates in the Surgical & Medical Instruments & Apparatus industry, as indicated by its Standard Industrial Classification (SIC) Code 3841.
When did OSR Holdings, Inc. change its name?
OSR Holdings, Inc. changed its name from Bellevue Life Sciences Acquisition Corp. on January 13, 2021, as detailed in the S-1/A filing.
What is OSR Holdings' status regarding SEC filing requirements?
OSR Holdings, Inc. is classified as an 'emerging growth company' and a 'non-accelerated filer,' which impacts its reporting obligations under SEC rules.
What are the potential risks for investors in OSR Holdings?
Potential risks for investors in OSR Holdings include those associated with an 'emerging growth company' status, the uncertainties of a 'delayed or continuous basis' offering under Rule 415, and general market risks inherent in the medical device sector.
Where are OSR Holdings, Inc.'s principal executive offices located?
The principal executive offices of OSR Holdings, Inc. are located at 10900 NE 4th Street, Suite 2300, Bellevue, WA 98004, with a business phone number of (425) 635-7700.
Who is the legal counsel for OSR Holdings, Inc. in this filing?
Jacqueline Jamin Drohan, Esq. of Drohan Lee LLP, located at 5 Penn Plaza, New York, NY 10001, is listed as legal counsel for OSR Holdings, Inc. in this S-1/A filing.
What is the registration number for OSR Holdings' S-1 filing?
The registration number for OSR Holdings, Inc.'s S-1 filing, as amended by this S-1/A, is 333-287626.
What does 'delayed or continuous basis' mean for OSR Holdings' offering?
A 'delayed or continuous basis' offering, checked under Rule 415 in the S-1/A, means OSR Holdings, Inc. intends to sell its securities over an extended period rather than in a single, immediate transaction, allowing for flexibility in market timing.
Risk Factors
- Continuous Offering Risks [medium — market]: The company is registering securities for sale on a delayed or continuous basis under Rule 415. This method of offering can create uncertainty regarding the timing and volume of securities sold, potentially impacting market price and investor perception.
- Emerging Growth Company Risks [medium — market]: As an emerging growth company, OSR Holdings, Inc. faces risks associated with limited operating history and potential challenges in establishing market presence and brand recognition within the competitive medical device sector.
- Medical Device Industry Competition [high — market]: The surgical and medical instruments and apparatus sector is highly competitive. OSR Holdings, Inc. must contend with established players and innovative new entrants, which could affect its ability to gain market share and achieve profitability.
Industry Context
OSR Holdings, Inc. operates in the surgical and medical instruments and apparatus sector, a segment characterized by rapid technological advancements and stringent regulatory oversight. The industry is competitive, with established global players and innovative startups vying for market share. Key trends include the increasing demand for minimally invasive surgical tools, advancements in diagnostic imaging equipment, and the integration of digital technologies for enhanced patient care and data management.
Regulatory Implications
As a company in the medical device industry, OSR Holdings, Inc. faces significant regulatory hurdles, including FDA approval processes for new products and ongoing compliance with quality system regulations. The S-1/A filing itself is a regulatory requirement to offer securities to the public, necessitating adherence to SEC disclosure rules.
What Investors Should Do
- Monitor future filings for detailed financial performance and use of proceeds.
- Evaluate competitive positioning within the medical device market.
- Assess management's execution strategy for the continuous offering.
Key Dates
- 2025-06-10: Filing of S-1/A Amendment — Indicates the company is proceeding with its public offering registration, allowing for delayed or continuous sale of securities.
- 2021-01-13: Name Change to OSR Holdings, Inc. — Marks a significant corporate identity change from Bellevue Life Sciences Acquisition Corp., potentially signaling a shift in strategic focus or operational direction.
Glossary
- S-1/A
- An amendment to a Form S-1 registration statement filed with the SEC. It is used to update or correct information previously filed in the initial S-1. (This filing indicates OSR Holdings, Inc. is amending its initial registration to proceed with a public offering.)
- Rule 415
- SEC rule that permits companies to register securities for delayed or continuous offerings over a period of time, rather than all at once. (OSR Holdings, Inc. is utilizing this rule, meaning the securities will be offered over time, not in a single event.)
- Emerging Growth Company
- A company that has total annual gross revenues of less than $1.235 billion during its most recently completed fiscal year. These companies are subject to reduced disclosure and regulatory requirements. (OSR Holdings, Inc. qualifies for this status, which may affect the scrutiny and reporting obligations associated with its public offering.)
- Non-accelerated Filer
- A type of filer that does not meet the thresholds for accelerated or large accelerated filer status, typically indicating a smaller market capitalization and less public float. (This classification suggests OSR Holdings, Inc. may have a smaller market presence compared to larger, more established public companies.)
- SIC Code 3841
- Standard Industrial Classification code for 'Surgical & Medical Instruments & Apparatus'. (This code categorizes OSR Holdings, Inc.'s primary business operations within the medical device manufacturing and distribution sector.)
Year-Over-Year Comparison
This filing is an amendment to an S-1 registration statement, not a periodic report like a 10-K or 10-Q. Therefore, direct year-over-year comparisons of financial metrics such as revenue growth, margins, or debt levels are not possible based on this document alone. The primary focus of this S-1/A is to update the registration for a continuous offering and confirm the company's status as an emerging growth company and non-accelerated filer. New risks related to the continuous offering mechanism and the general market risks for an emerging growth company in the medical device sector are highlighted.
Filing Details
This Form S-1/A (Form S-1/A) was filed with the SEC on June 10, 2025 by Kuk Hyoun Hwang regarding OSR Holdings, Inc. (OSRHW).